55
total announcements
524715.BO · 15 min delayed
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the resignation of Mr. Gautam Doshi as a Non-Executive, Independent Director, citing personal reasons. The company has also approved the issuance of non-convertible debentures worth up to INR 10,000 Crore.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the outcome of its board meeting held on 12 October 2026, where it approved the issuance of non-convertible debentures up to INR 10,000 Crore and accepted the resignation of Mr. Gautam Doshi as a Non-Executive Independent Director.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/10/2026 to consider and approve the issuance of listed, rated, unsecured, redeemable, non-convertible debentures.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has established an endowed professorship at Mount Sinai to advance dermatologic care. The $2.5 million endowment will fund academic leadership in dermatology in perpetuity, beginning with Dr. Mark G. Lebwohl as its inaugural incumbent. The professorship will advance research and training, helping translate emerging knowledge into better care and prepare future leaders in the field.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has published newspaper advertisements containing information about Postal Ballot/E-Voting, and has also made available copies of the newspaper clippings on its website.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd is conducting a Postal Ballot/E-voting to seek shareholders' approval for various items, including the Sun Pharma Employees Stock Option Plan 2026 and enabling approvals for the proposed acquisition of Organon & Co.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd announced that its drug LEQSELVI (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including a featured oral presentation reporting long-term safety results from a European open-label extension study evaluating up to two years of treatment in adults with severe alopecia areata.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has published a newspaper advertisement and social media post regarding the opening of a special window for the transfer of physical shares, which were sold or purchased prior to April 1, 2019.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has submitted its ESG Overview for FY 2025-26, highlighting a 15.86% reduction in absolute carbon emissions and a 16.05% reduction in absolute water consumption compared to the baseline year 2020.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has completed its postal ballot process initiated on August 25, 2026, and the shareholders have approved the resolution by the requisite majority.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced a global licensing agreement with LIB Therapeutics for the commercialization and manufacturing of lerodalcibep, a PCSK9 inhibitor, excluding the US and China. The agreement strengthens Sun Pharma's Innovative Medicines portfolio and provides access to a $3.7 billion PCSK9 market.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has received approval from its shareholders to reclassify certain persons from the 'Promoter Group' to the 'Public' category, as per SEBI Listing Regulations.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the closure of its trading window from 01 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30 September 2026.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has released an investor presentation for September 2026, highlighting its revenue composition, growth highlights, business operations, R&D & Manufacturing, corporate governance, key financials, company history, and focus areas.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's and S&P Global, with ratings of Baa1 and BBB+ respectively, reflecting the strength of Sun Pharma's business and financial profile, and taking into account its proposed acquisition of Organon & Co.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the schedule of upcoming analyst/institutional investor meetings, including UBS India Summit 2026, Jefferies India Forum 2026, and J.P. Morgan India Conference 2026, without disclosing any unpublished price sensitive information.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd participated in a White House ceremony to announce agreements with the U.S. government to prioritize access to affordable medicines for millions of American patients.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has published newspaper advertisements containing information about Postal Ballot/E-Voting.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced a notice of postal ballot/e-voting for the reclassification of certain individuals from the 'Promoter Group' to the 'Public' category, which will reduce the promoter group holding from 54.48% to 52.68% and increase public holding from 45.52% to 47.32%. The reclassification is subject to requisite approvals and will not affect control, management, or business operations.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the schedule of upcoming analyst/institutional investor meetings, to be held on 01-Sept-26 at Ashwamedh – Elara India Dialogue 2026 in Mumbai. The company will not disclose any unpublished price sensitive information at these meetings.